参考文献/References:
[1] Nú.EZ-GIL I J, BAUTISTA D, CERRATO E, et al. Incidence, management, and immediate- and long-term outcomes after iatrogenic aortic dissection during diagnostic or interventional coronary procedures[J]. Circulation, 2015, 131(24): 2114-2119.
[2] 吴彩云，何伟平，孙志刚．高敏 C反应蛋白、纤维蛋白原与冠脉支架内再狭窄的关系 [J].实用临床医学 , 2019, 20(2):16-18. WU Caiyun, HE Weiping, SUN Zhigang. Relationship between high sensitive C-reactive protein, fibrinogen and in stent restenosis [J]. Practical Clinical Medicine, 2019,20 (2): 16-18.
[3] HEODOROPOULOS K, MENNUNI M G, DANGAS G D, et al. Resistant in-stent restenosis in the drug eluting stent era[J]. Catheterization and Cardiovascular Interventions, 2016, 88(5): 777-785.
[4] WANG Zhichao, LIU Chi, FANG Hong. Blood cell parameters and predicting coronary in-stent restenosis[J]. Angiology, 2019, 70(8): 711-718.
[5] QIN Zheng, ZHOU Kuo, LI Yueping, et al. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study [J]. Cardiovascular Diabetology, 2019, 18(1): 11.
[6] YU Xiaolan, LU Jianping, LI Jingjing, et al. Serum triglyceride lipase concentrations are independent risk factors for coronary artery disease and in-stent restenosis [J]. Journal of Atherosclerosis and Thrombosis, 2019, 26(9): 762-774.
[7] 王聪霞，贾珊．冠状动脉支架内再狭窄发生机制的研究进展 [J].西安交通大学学报（医学版） , 2018, 39(3): 303-309. WANG Congxia, JIA Shan. Advances in the mechanism of restenosis after percutaneous coronary intervention[J]. Journal of Xi’an Jiaotong University(Medical Sciences)，2018,39 (3): 303-309.
[8] KAI H, IKEDA H, YASUKAWA H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes[J]. Journal of the American College of Cardiology, 1998, 32(2): 368-372.
[9] BENCH T J, JEREMIAS A, BROWN D L. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease[J]. Pharmacological Research, 2011, 64(6): 561-566.
[10] 邓意，陈立珩，王先宝，等．冠心病患者血清Ⅰ型胶原羧基末端肽的表达变化及临床意义 [J].南方医科大学学报 , 2015,35 (4): 506-510. DENG Yi, CHEN Liheng, WANG Xianbao, et al. Changes in serum level of carboxy-terminal telopeptide of type I collagen in patients with coronary heart disease[J]. Journal of Southern Medical University, 2015,35 (4): 506-510.
[11] BETON O, ARSLAN S, ACAR B, et al. Association between MMP-3 and MMP-9 polymorphisms and coronary artery disease[J]. Biomedical Reports, 2016, 5(6): 709-714.
[12] ARSENAULT B J, KOHLI P, LAMBERT G, et al. Emerging cardiovascular disease biomarkers and incident diabetes mellitus risk in Statin-Treated patients with coronary artery disease (from the treating to new targets [TNT] study)[J]. The American Journal of Cardiology, 2016, 118(4): 494-498.
[13] 杨丽．冠心病患者 PCI术后支架内再狭窄与基质金属蛋白酶 9的关系 [J].中国现代药物应用 , 2016, 10(16): 82-83. YANG Li. The relationship between in stent restenosis and matrix metalloproteinase-9 in patients with coronary heart disease after PCI [J]. Chinese Journal of Modern Drug Application, 2016,10 (16): 82-83.
[14] 牛晓婷，徐阳，郑阳，等．半乳糖凝集素 -3和基质金属蛋白酶 -9与支架内再狭窄的关系 [J].西安交通大学学报（医学版）, 2018,39 (4): 483-487, 503. NIU Xiaoting, XU Yang, ZHENG Yang, et al. Association of in-stent restenosis with serum Gal-3 and MMP-9 levels [J]. Journal of Xi’an Jiaotong University(Medical Sciences)，2018,39 (4): 483-487,503.
[15] 赵婉晴，高伟勤．基质金属蛋白酶及其抑制剂在心血管疾病中的研究进展 [J].微量元素与健康研究， 2020, 37(1): 63-65. ZHAO Wanqing, GAO Weiqin. Advances in studies on matrix metalloproteinase and their inhibitors in cardiovascular diseases[J]. Studies of Trace Elements and Health, 2020, 37(1): 63-65.
[16] 胡茜，石增刚，桑更生，等．基质金属蛋白酶 -9/ 基质金属蛋白酶抑制物 -1比值与急性冠脉综合征 [J].淮海医药 , 2015, 33(4): 325-327. HU Qian, SHI Zenggang, SANG Gengsheng, et al. Changes of MMP-9/TIMP-1 ratio in patients with acute coronary syndrom[J]. Journal of Huaihai Medicine, 2015, 33(4): 325-327.
[17] LINDSEY M L, YABLUCHANSKIY A, MA Yonggang. Tissue inhibitor of metalloproteinase-1: actions beyond matrix metalloproteinase inhibition[J]. Cardiology, 2015, 132(3): 147-150.
[18] 李泽民，梁记华，闫世冉．心肌梗死患者细胞外基质金属蛋白酶诱导因子表达量与炎症反应、 MMPs/ TIMPs的相关性 [J]．海南医学院学报， 2018, 24(20): 1791-1794. LI Zemin, LIANG Jihua, YAN Shiran. Correlation of extracellular matrix metalloproteinase inducer expression with inflammatory response and MMPs/ TIMPs in patients with myocardial infarction [J]. Journal of Hainan Medical University, 2018, 24(20): 1791-1794.
[19] PETERSEN E, W.GBERG F, ANGQUIST K A. Proteolysis of the abdominal aortic aneurysm wall and the association with rupture[J]. European Journal of Vascular and Endovascular Surgery, 2002, 23(2): 153-157.
[20] 康彬，陈树涛，冯津萍．探讨 MMP-9, TIMP-1, MMP-9/TIMP-1及 ICTP与冠心病的相关性 [J].中国医学创新 , 2015, 12(12): 18-21. KANG Bin, CHEN Shutao, FENG Jinping. Relationship between MMP-9, TIMP-1, MMP-9/ TIMP-1, ICTP and coronary heart disease[J]. Medical Innovation of China, 2015, 12(12): 18-21.
[21] 顾遵才，李勋，王正忠，等．血清血管内皮生长因子B检测在急性心肌梗死患者预后评判中的作用[J].中国动脉硬化杂志 , 2016, 24(6): 611-614. GU Zuncai, LI Xun, WANG Zhengzhong, et al. Effects of serum vascular endothelial growth factor-B measurement in the prognosis evaluation of patients with acute myocardial infarction[J]. Chinese Journal of Arteriosclerosis, 2016, 24(6): 611-614.
[22] 苗建波，安少波，徐雷，等．血管内皮生长因子对兔腹主动脉支架植入后血管内皮功能的影响研究 [J].重庆医学，2018，47（29）：3739-3742． MIAO Jianbo, AN Shaobo, XU Lei, et al. Effect of vascular endothelial growth factor on vascular endothelial function after abdominal aortic stent implantation in rabbits[J]. Chongqing Medicine, 2018, 47(29): 3739-3742.
[23] 周江，郭靖涛，王福华，等．血管内皮生长因子与急性心肌梗死介入治疗术后再狭窄研究进展 [J].河北医学 , 2014, 20(12): 2138-2141. ZHOU Jiang, GUO Jingtao, WANG Fuhua, et al. Research progress of vascular endothelial growth factor and restenosis after interventional therapy for acute myocardial infarction[J]. Hebei Medicine, 2014, 20(12): 2138-2141.
[24] MAZIDI M, REZAIE P, KENGNE A P, et al. VEGF, the underlying factor for metabolic syndrome, fact or .ction [J]. Diabetes & Metabolic Syndrome, 2017, 11 (Suppl 1): S61-S64.
[25] 谢林涧，李骊华．血管内皮生长因子在心血管疾病中的作用 [J]．国际心血管病杂志 , 2019, 46(4): 219-222. XIE Linjian, LI Lihua. The role of vascular endothelial growth factor in cardiovascular disease [J]. International Journal of Cardiovascular Disease, 2019,46 (4): 219-222.
[26] 张燕，陈岩 ,李庆民 , 等 .血清骨保护素与基质金属蛋白酶 -9水平与经皮冠脉介入术后支架内再狭窄的研究 [J].医药论坛杂志 , 2017, 38(4): 4-6. ZHANG Yan, CHEN Yan, LI Qingmin, et al. Study on relationship between levels of osteoprotegerin and matrix metalloproteinase-9 and restenosis after percutaneous coronary intervention [J]. Journal of Medical Forum, 2017, 38(4): 4-6.
[27] 杨敏，刘奇峰，蓝新平，等．急性冠脉综合征患者血清 Periostin, VEGF, CRP检测及与心肌损伤的关系 [J].海南医学院学报 , 2015, 21(7): 898-900, 904. YANG Min, LIU Qifeng, LAN Xinping, et al. Crrelation of serum Periostin, VEGF, CRP contents with myocardial damage in acute coronary syndrome patients[J]. Journal of Hainan Medical University, 2015,21 (7): 898-900, 904.